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Using current release technology, oral delivery for 24 h is possible for many drugs;
however, the substance must be well absorbed throughout the whole gastrointestinal
tract. A significant obstacle may arise if there is a narrow window for drug absorption in
the gastrointestinal tract (GIT), if a stability problem exists in gastrointestinal fluids, or
the drug is poorly soluble in the intestine or acts locally in the stomach. Thus, the real is-
sue in the development of oral controlled release dosage forms is not just to prolong the
delivery of the drugs for more than 12 h, but to prolong the presence of the dosage
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Floating matrix tablets of norfloxacin were developed to
prolong gastric residence time, leading to an increase in
drug bioavailability. Tablets were prepared by the wet
granulation technique, using polymers such as hydroxy-
propyl methylcellulose (HPMC K4M, HPMC K100M) and
xanthan gum. Tablets were evaluated for their physical
characteristics, viz., hardness, thickness, friability, and mass
variation, drug content and floating properties. Further,
tablets were studied for in vitro drug release characteris-
tics for 9 hours. The tablets exhibited controlled and pro-
longed drug release profiles while floating over the dis-
solution medium. Non-Fickian diffusion was confirmed
as the drug release mechanism from these tablets, indi-
cating that water diffusion and polymer rearrangement
played an essential role in drug release. The best formu-
lation (F4) was selected based on in vitro characteristics
and was used in vivo radiographic studies by incorporat-
ing BaSO4. These studies revealed that the tablets rema-
ined in the stomach for 180 ± 30 min in fasting human
volunteers and indicated that gastric retention time was
increased by the floating principle, which was consid-
ered desirable for the absorption window drugs.
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forms in the stomach or somewhere in the upper intestine until all of the drug is relea-
sed over the desired period of time (1).
Controlled gastric retention of solid dosage forms may be achieved by the mecha-
nisms of floating systems, swelling and expanding systems, bioadhesive systems, modi-
fied shape systems, high density systems or other delayed gastric emptying devices. The
principle of buoyant preparation offers a residence time for the dosage form and sus-
tained drug release (2).
The various buoyant preparations include microballoons, granules, powders, cap-
sules, tablets, and laminated films (2). Based on the mechanism of buoyancy, two dis-
tinctly different technologies, i.e., non-effervescent and effervescent systems, have been
utilized in the development of floating systems. Non-effervescent systems commonly use
gel-forming or highly swellable cellulose type hydrocolloids, polysaccharides and ma-
trix forming polymers such as polycarbonate, polyacrylate, polymethacrylate, and poly-
styrene. Effervescent systems utilize matrices prepared with swellable polymers such as
methocel or chitosan and effervescent compounds, e.g., sodium bicarbonate and citric or
tartaric acid (3), or matrices containing chambers of liquid that gasify at body tempera-
ture (4). Chavampatil et al. (5) have developed the gastroretentive drug delivery system
(GRDDS) for ofloxacin with different polymers such as psyllium husk, HPMC K100M,
crosspovidone and their combinations in order to get the desired sustained release pro-
file over a period of 24 h. Varshosaz et al. (6) developed ciprofloxacin floating and bio-
adhesive extended release tablets to increase the duration of the drug presence in its ab-
sorption area.
Norfloxacin is a flouroquinolone, broad spectrum antibiotic, and is used in the
treatment of urinary tract infections, prostatitis and gonorrhea. Norfloxacin is least ab-
sorbed from the lower part of the gastrointestinal tract and is better absorbed from the
stomach. This drug has a repetitive dose schedule (400 mg twice daily) (7), short biologi-
cal half-life (3–4 h) (8, 9) and reduced bioavailability (30–40 %) (9). Thus, norfloxacin is a
candidate for the development of a gastroretentive drug delivery system. In this work,




Norfloxacin was a generous gift sample from Dr. Reddy’s Labs, India. Hydroxy-
propyl methylcellulose (HPMC K4M and HPMC K100M) and xanthan gum were pur-
chased from Colorcon Asia Pvt. Ltd, and Kanwarlal Industries, India, respectively. All
other chemicals used were of analytical grade.
Development of tablets
Accurately weighed quantities (as specified in Table I) of norfloxacin, HPMC K4M,
HPMC K100M, xanthan gum and sodium bicarbonate were passed through a 0.425-mm
sieve to get uniform size particles, then they were mixed geometrically for 5 to 10 min-
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utes and the mixture was placed in a polyethylene bag and further mixed for 5 minutes
to ensure a homogeneous mass. Accurately weighed quantity of PVPK-30 was dissolved
in isopropyl alcohol (IPA) to prepare a binder solution. The binder solution was added
to the dry blend gradually with constant kneading to form a homogeneous mass. The
dough mass was passed through a 2.0-mm sieve and the granular mass was allowed to
dry at room temperature. The granules were passed through a 1.18-mm sieve. These gra-
nules were lubricated with magnesium stearate and talc and compressed into tablets us-
ing a 16-station punching machine (Rimek, India). The tablets were oblong of 16 mm
length and a thickness of 5.9–6.1 mm.
Characterization of floating tablets
The prepared floating tablets were evaluated for mass uniformity (20 tablets), hard-
ness (6 tablets) was measured by a hardness tester (Erweka tester, Germany), thickness
(10 tablets) was measured using a vernier caliperse (Mitutoyo Corporation, Japan) and
friability was determined (10 tablets) using a Roche friabilator (Germany).
The drug content in each formulation was determined by triturating 10 tablets and
a quantity of powder equivalent to the mass of one tablet was transferred into a 100-mL
volumetric flask. To this, 50 mL of 0.1 mol L–1 HCl was added and then the solution was
subjected to sonication for about 2 h. The solution was made up to the mark with 0.1
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F1 160 – – 100 10 15 –
F2 140 – – 100 20 25 –
F3 100 – – 100 55 30 –
F4 120 – – 100 35 30 –
F5 – 120 – 80 5 30 –
F6 – 100 – 80 25 30 –
F7 – 90 – 80 35 30 –
F8 – 80 – 80 45 30 –
F9 – 70 – 80 55 30 –
F10 – – 140 120 55 20 –
F11 – – 100 120 95 20 –
F12 – – 80 120 115 20 –
F13 – – 80 120 65 20 50
F14 – – 100 120 45 20 50
F15 – – 140 120 5 20 50
F16 – – 130 120 15 20 50
All the tablets contain 400 mg norfloxacin, 7 mg magnesium stearate and 8 mg talc.
HPMC – hydroxypropyl methylcellulose, PVP – polyvinyl pyrrolidone, DCP – dicalcium phosphate
mol L–1 HCl, filtered and suitable dilutions were prepared with 0.1 mol L–1 HCl. The
drug content was estimated by recording absorbance at 278 nm by using a UV-Visible
spectrophotometer (Shimadzu U.V. – 2201, Japan).
In vitro buoyancy studies
The in vitro buoyancy was determined by the floating lag time. The tablets were
placed in a 100-mL beaker containing 0.1 mol L–1 HCl. The time required for the tablet to
rise to the surface for floating was determined as the floating lag time and further float-
ing duration of all tablets was determined by visual observation.
In vitro drug release studies
The in vitro drug release studies were conducted using the USP 28 type II (10) (pad-
dle) dissolution apparatus (TDT-06T, Electrolab, India). Hydrochloric acid (pH 1.2), 750
mL, was used as medium. The study was conducted at 37 ± 0.5 °C and at paddle rota-
tion of 50 rpm. Samples of 5 mL were collected at predetermined time intervals and re-
placed with fresh hydrochloric acid. The samples were filtered and diluted and the drug
content in the samples was estimated at 278 nm.
Mathematical models, zero-order, first-order, Higuchi and Peppas were applied to
analyze the release mechanism and pattern (11–13).
Tablets for in vivo radiographic studies
Tablets of 6.103 ± 0.012 mm thickness and of 700 ± 4 mg mass were prepared. To
make the tablet X-ray opaque, incorporation of BaSO4 was necessary. For this purpose,
100 mg of the drug was replaced with BaSO4 (100 mg BaSO4 + 300 mg norfloxacin) and
all other ingredients were kept constant. The tablets were characterized for hardness,
floating lag time and floating duration.
In vivo radiographic studies
The protocol of radiographic studies on healthy human volunteers was approved
by the Human Ethical Committee, University College of Pharmaceutical Sciences, Ka-
katiya University, India. The study was conducted on four healthy male volunteers, wei-
ghing between 55–75 kg and in the age group of 25 ± 2 years. The tablets prepared for
radiography (F4) were administered orally with a glass of water. During the study, the
subjects were not allowed to eat but water was available ad libitum. After ingestion of F4
floating tablets containing barium sulphate, the volunteers were exposed to X-ray pho-
tography in the abdominal region. The X-ray photographs were taken at 0.5, 1.5, 3, 4 and
5 h after administration of the tablets. The mean gastric residence time was calculated.
214
R. Bomma et al.: Development and evaluation of gastroretentive norfloxacin floating tablets, Acta Pharm. 59 (2009) 211–221.
RESULTS AND DISCUSSION
Characterization of tablets
The hardness of formulations F2-F16 was found to be between 8–8.6 kg cm–2, except
for F1 with hardness of 9.6 ± 0.2 kg cm–2, indicating satisfactory mechanical strength.
The thickness of prepared formulations was between 5.9 and 6.1 mm. The friability was
in the range of 0.14–0.27 % for all the formulations, which was an indication of good me-
chanical resistance of the tablet. The average drug content of tablets (n = 10) varied be-
tween 95.5 and 98.9 %, indicating content uniformity of the prepared formulations.
In vitro buoyancy studies
Norfloxacin tablets were prepared using polymers such as HPMC K4M, HPMC
K100M and xanthan gum. Formulations F1-F4, F5-F9 and F10-F16 were prepared with
HPMC K4M, HPMC K100M and xanthan gum, respectively. Sodium bicarbonate was
added as a gas generating agent. Whitehead et al. (14) have demonstrated good correla-
tion between in vitro and in vivo buoyancy of floating dosage forms. In this study, pene-
tration of water into tablets prepared with xanthan gum was rather slow, causing de-
layed gel formation and subsequent increase in the floating lag time compared to the
tablets prepared with HPMC K4M and HPMC K100M. The best formulation (F4)
showed a floating lag time of 35 ± 4 s, hardness of 8.04 ± 0.19 kg, thickness of 6.09 ± 0.01
mm, friability of 0.21 %, content uniformity of 97.3 ± 0.9 % and mass variation of 700 ± 3
mg. Further, it also showed a drug release of 94.3 ± 1.5 % over 9 h. The floating lag time
and duration of floating for the tablets are given in Table II. In general, all the prepared
tablets floated for 24 h.
In vitro dissolution studies
The pharmacokinetic parameters of norfloxacin were used to calculate a theoretical
drug release profile for a 12-h dosage form (15). The in vitro drug release studies re-
vealed that formulations F1, F2 and F4 showed a release of 69.5, 82.1 and 94.3 %, respec-
tively, in 9 h (Fig. 1a). Formulation F3 showed maximum drug release of 96.5 % in 8 h.
The variation in drug release was due to different polymer concentrations in all the four
formulations. The immediate release part for sustained release of norfloxacin was calcu-
lated and was found to be 77.8 mg (19.5 %) of the drug in 1 hour.
It is expected that the developed formulation should have the following theoretical
drug release profile, i.e., 20 to 25 % in 1 h, 25 to 45 % in 2 h, 55 to 75 % in 4 h, 65 to 85 %
in 6 h and 85 % after 8 h. Formulations F1-F3 failed to meet the needed theoretical drug
release profile. Formulation F4 met the needed theoretical drug release profile and
floated with a lag time of 35 s; for these reasons, it was considered the best formulation
among all the four formulations of this series.
Formulations F5-F9, composed of HPMC K100M, showed a release of 60.4, 76.0,
83.7, 87.4 and 96.5 % in 9 h, respectively (Fig. 1b). These variations in drug release were
due to changes in polymer concentrations of the tablets. However, formulations F5-F8
failed to meet the required theoretical drug release profile. Formulation F9 met the de-
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sired theoretical drug release profile and floated with a lag time of 25 s. It was, therefore,
considered the best formulation among all the five formulations of this series.
Drug release profiles of formulations F10-F16, composed of xanthan gum, are
shown in Fig. 1c. The percentage of drug released from formulations F10, F11 and F12
was 66.8, 74.3 and 77.3, respectively, in 9 h. This variation was considered to be due to
different polymer concentrations in formulations. Further, these three formulations
failed to meet the required theoretical drug release profile. In addition, these formula-
tions showed very long floating lag times. To reduce the floating lag time, lactose was
added to the remaining formulations. Formulations F13-F16, composed of xanthan gum
and varying ratios of lactose, showed a drug release of 98.6 (5 h), 96.3 (7 h), 85.7 (9 h)
and 93.4 (9 h), respectively. Further, formulations F13-F15 failed to meet the needed theo-
retical drug release profile. However, formulation F16 met the theoretical drug release
profile and floated with a lag time of 570 s. Therefore, formulation F16 was considered
the best formulation among all the seven formulations of this series. After incorporation
of lactose, the drug release was increased due to the capillary action of lactose, which fa-
cilitated higher drug release without affecting the matrix. t50 (time required for releasing
50 % of the drug) and DE (%) (dissolution efficiency) are the parameters used to com-
pare the relative efficacy of dosage forms. Decreasing the content of polymers such as
HPMC and xanthan gum in tablets, reduced t50 but increased the DE (%) (Table II).
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Fig. 1. Drug release profiles of norfloxacin
floating tablets prepared with: a) HPMC
K4M; b) HPMC K100M and c) xanthan gum
(mean ± SD, n = 3).
Among several methods investigated for dissolution profile comparison, the f2 fac-
tor is the simplest and most applicable. Moore et al. (16) proposed a model independent
mathematical approach to compare dissolution profiles using two factors, f1 and f2.
FDA (17) has set a public standard of f2 value between 50 and 100 to indicate similarity
between two dissolution profiles. Optimized formulations from each series (F4, F9 and
F16) showed similar in vitro drug release profiles to that of the theoretical drug release
profile, which was evident from the calculated factors f1 and f2 values (F4: f1 = 7 and
f2 = 66, F9: f1 = 9 and f2 = 63, F16: f1 = 9 and f2 = 63).
Drug release kinetics
The tablet containing a polymeric matrix builds, on contact with water, a gel layer
around the tablet core, which governs the drug release. It is known that the drug release
from HPMC matrices is controlled for water soluble drugs by diffusion through the gel
layer or, for poorly soluble drugs, by erosion of the outer polymer chains (18). Hence,
the kinetics of swelling is important because the gel barrier is formed with water pene-
tration. The drug release rate kinetics was calculated for zero order, first order and
Higuchi models (Table III).
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Table II. Physical properties, dissolution efficiency DE and t50
Formulation Floating lag timea Duration of floatinga DE (%)a t50 (h)a
F1 70 ± 8 23.65 ± 0.25 69.7 ± 0.9 5.46 ± 0.04
F2 55 ± 8 24.05 ± 0.30 82.1 ± 1.3 4.86 ± 0.11
F3 60 ± 4 23.30 ± 0.22 96.5 ± 1.2 3.10 ± 0.07
F4 35 ± 4 23.45 ± 0.16 94.3 ± 1.9 3.16 ± 0.04
F5 50 ± 2 24.25 ± 0.15 60.4 ± 2.1 6.30 ± 0.10
F6 35 ± 1 24.10 ± 0.35 76.0 ± 0.7 5.16 ± 0.02
F7 30 ± 2 23.35 ± 0.19 83.7 ± 2.1 4.88 ± 0.03
F8 25 ± 2 24.40 ± 0.10 87.4 ± 1.0 4.20 ± 0.07
F9 25 ± 2 23.45 ± 0.20 96.5 ± 0.8 2.98 ± 0.18
F10 1860 ± 29 23.35 ± 0.27 66.8 ± 1.8 5.82 ± 0.18
F11 1500 ± 24 23.50 ± 0.26 74.3 ± 1.2 5.28 ± 0.04
F12 1380 ± 16 24.20 ± 0.19 77.8 ± 2.4 4.80 ± 0.18
F13 510 ± 4 23.37 ± 0.29 b 1.94 ± 0.19
F14 540 ± 10 23.40 ± 0.09 c 2.22 ± 0.06
F15 600 ± 11 23.35 ± 0.15 85.7 ± 1.6 3.77 ± 0.18
F16 570 ± 4 23.45 ± 0.12 93.4 ± 1.6 3.06 ± 0.09
a Mean ± SD, n = 3.
b 98.6 % of the drug was released in 5 h.
c 96.3 % of the drug was released in 7 h.
Drug diffusion through most types of polymeric systems is often best described by
Fickian diffusion, but in addition to diffusion, other processes are also important. There
is also relaxation of the polymer chains that influences the drug release mechanisms.
This process is described as non-Fickian or anomalous diffusion. Release from initially
dry, hydrophilic glassy polymers, that swell when added to water and become rubbery,
shows anomalous diffusion as a result of the arrangement of macromolecular chains.
The thermodynamic state of the polymer and the penetrant concentration are responsi-
ble for the different types of diffusion. A third class of diffusion is case II diffusion,
which is a special case of non-Fickian diffusion (13). A simple semiempirical equation
can be used to analyze data of controlled release of water-soluble drugs from polymer






where Mt is the amount of the drug released at time t, M∞ is the overall amount of the
drug (whole drug), b is the constant incorporating structural and geometric characteris-
tics of the controlled release device and n is the release exponent indicative of the drug
release mechanism. For tablets of a known geometry (in this case a slab) n = 0.5 means
Fickian diffusion, 0.5 < n < 1.0 non-Fickian diffusion, and n = 1.0 case II diffusion (13).
Regarding the n values calculated for the studied tablets (Table III), in most cases a non-
-Fickian mechanism was found to be predominant, which indicated that water diffusion
as well as polymer rearrangement played an essential role in drug release.
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Table III. Correlation coefficient (R2) and release exponent (n) values for different kinetic models
Formulation Zero-order First-order Higuchi n
F 1 0.9819 0.9887 0.9413 0.9537
F 2 0.9862 0.9562 0.9578 0.7995
F 3 0.9321 0.9732 0.9565 0.4596
F 4 0.9582 0.9683 0.9820 0.7371
F 5 0.9794 0.9959 0.9808 0.916
F 6 0.9897 0.9927 0.9629 0.8975
F 7 0.9875 0.9452 0.9552 0.803
F 8 0.9843 0.9790 0.9522 0.7981
F 9 0.9492 0.9531 0.9628 0.7334
F 10 0.9743 0.9983 0.9768 0.7547
F 11 0.9828 0.9910 0.9696 0.7845
F 12 0.9723 0.9811 0.9832 0.6487
F 13 0.9766 0.8694 0.9744 0.5464
F 14 0.9428 0.9428 0.9973 0.5701
F 15 0.9561 0.9686 0.9892 0.6341
F 16 0.9421 0.9900 0.9841 0.6828
The passage of a water-soluble drug through the hydrated gel layer around the ma-
trix tablet is approximately dependent on the square root of time and can be described
in the following form (11):
Qt = kt1/2
where Qt is the amount of the drug released in time t, k is the kinetic constant.
Intra-gastric behavior of floating tablets
The BaSO4-containing floating tablets showed a floating lag time of 125 ± 5 s, hard-
ness of 8.16 ± 0.02 kg cm–2 and thickness of 6.103 ± 0.012 mm. The tablets were clearly
seen in the GIT at different positions during the study (Fig. 2). The average residence
time was found to be 180 ± 30 min (n = 4).
CONCLUSIONS
Systematic studies were conducted using three different polymers in different con-
centrations to prepare norfloxacin floating tablets. Optimized formulations F4 and F9
with HPMC floated with a lag time of less than 1 minute and continued to float for 24 h.
Formulation F16, with xanthan gum, floated with a lag time of 9 min and continued to
float for 24 h. Floating lag time of xanthan gum tablets was reduced by using lactose. In
vivo radiographic studies revealed that F4 tablets remained in the stomach for 180 ± 30
min, which indicated that GRT was increased by the floating principle and was consid-
ered desirable for improving bioavailability of the absorption window drugs.
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Fig. 2. Radiographic images showing the presence of a BaSO4-loaded floating tablet in the stomach
at different time periods (the tablet is indicated with an arrow). The tablet altered its position in the
stomach. Images were taken after: a) 0.5 h, b) 1.5 h, c) 3 h, and d) 4 h, after tablet administration.
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S A @ E T A K
Razvoj i vrednovanje plutaju}ih tableta norfloksacina
s produljenim zadr`avanjem u `elucu
RAMESH BOMMA, RONGALA APPALA SWAMY NAIDU, MADHUSUDAN RAO YAMSANI i KISHAN VEERABRAHMA
Razvijene su plutaju}e tablete norfloksacina koje se produljeno zadr`avaju u `elucu
i time pove}avaju bioraspolo`ivost. Tablete su pripravljene metodom vla`ne granulacije,
koriste}i hidroksipropil metilcelulozu (HPMC K4M, HPMC K100M) i ksantan gumu. Ta-
bletama su odre|ena fizikalna svojstva (~vrsto}a, debljina, lomljivost i varijacija mase) te
sadr`aj ljekovite tvari i plutaju}a svojstva. Nadalje, pra}eno je osloba|anje ljekovite tvari
in vitro tijekom 9 h. Uo~eno je da je osloba|anje kontrolirano i produljeno te da tablete
plutaju u ispitivanom mediju. Mehanizam osloba|anja nije slijedio Fickov zakon, {to uka-
zuje da difuzija vode i promjene u strukturi polimera imaju bitnu ulogu u osloba|anju
ljekovite tvari. Najbolja formulacija (F4) in vitro uporabljena je za izradu pripravaka
barijevog sulfata za radiografska ispitivanja in vivo. Ispitivanja na volonterima koji su
apstinirali od hrane pokazala su da primjena plutaju}ih tableta produljuje vrijeme zadr-
`avanja u `elucu na 180 ± 30 min.
Klju~ne rije~i: norfloksacin, plutaju}e tablete, vrijeme zadr`avanja u `elucu, sustav za isporuku lije-
ka s produljenim zadr`avanjem u `elucu
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